Published in Blood on March 24, 2010
Regulation of immune responses by mTOR. Annu Rev Immunol (2011) 3.08
TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res (2010) 2.14
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
TOR in the immune system. Curr Opin Cell Biol (2011) 1.44
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem (2011) 1.31
Regulation of innate immune cell function by mTOR. Nat Rev Immunol (2015) 1.27
Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol (2011) 1.16
Tolerance induction by exosomes from immature dendritic cells and rapamycin in a mouse cardiac allograft model. PLoS One (2012) 1.15
The role of tuberous sclerosis complex 1 in regulating innate immunity. J Immunol (2012) 1.13
IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol (2014) 1.09
Tuberous sclerosis 1 (Tsc1)-dependent metabolic checkpoint controls development of dendritic cells. Proc Natl Acad Sci U S A (2013) 1.08
Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat Immunol (2015) 1.06
Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials. Front Immunol (2012) 1.03
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol (2013) 0.99
Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol (2011) 0.97
Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. J Immunol (2013) 0.93
Human tolerogenic DC-10: perspectives for clinical applications. Transplant Res (2012) 0.93
Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res (2012) 0.92
Interleukin-33 in health and disease. Nat Rev Immunol (2016) 0.92
Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro. Cancer Immunol Immunother (2010) 0.92
New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunol Rev (2015) 0.90
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci (2011) 0.90
NADPH oxidase-2 derived ROS dictates murine DC cytokine-mediated cell fate decisions during CD4 T helper-cell commitment. PLoS One (2011) 0.89
Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction. Blood (2013) 0.89
Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res (2012) 0.89
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin. J Immunol (2013) 0.87
Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res (2012) 0.85
Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling. Stem Cells (2013) 0.85
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation. J Transplant (2013) 0.85
Regulatory myeloid cells in transplantation. Transplantation (2014) 0.83
New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. Br J Clin Pharmacol (2016) 0.83
mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo. J Immunol (2015) 0.82
Rapamycin-conditioned, alloantigen-pulsed myeloid dendritic cells present donor MHC class I/peptide via the semi-direct pathway and inhibit survival of antigen-specific CD8(+) T cells in vitro and in vivo. Transpl Immunol (2011) 0.82
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation. Nat Rev Nephrol (2016) 0.82
Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant (2014) 0.81
Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells. Am J Transplant (2013) 0.80
Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry (2014) 0.80
Lipopolysaccharide derived from the digestive tract activates inflammatory gene expression and inhibits casein synthesis in the mammary glands of lactating dairy cows. Oncotarget (2016) 0.78
Impaired Cell Cycle Regulation in a Natural Equine Model of Asthma. PLoS One (2015) 0.78
Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J Leukoc Biol (2016) 0.78
Cutting edge: Flt3 ligand mediates STAT3-independent expansion but STAT3-dependent activation of myeloid-derived suppressor cells. J Immunol (2014) 0.77
Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro. J Gen Virol (2014) 0.76
IL-12hi rapamycin-conditioned dendritic cells mediate IFN-γ-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease. Biol Blood Marrow Transplant (2013) 0.76
Small GTPase Rab8a-recruited Phosphatidylinositol 3-Kinase γ Regulates Signaling and Cytokine Outputs from Endosomal Toll-like Receptors. J Biol Chem (2017) 0.75
The Effects of T4 and A3/R Bacteriophages on Differentiation of Human Myeloid Dendritic Cells. Front Microbiol (2016) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol (2005) 9.70
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J (1998) 7.59
Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol (2005) 7.13
CD4 T cells: fates, functions, and faults. Blood (2008) 7.03
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
The two TORCs and Akt. Dev Cell (2007) 6.17
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity (2007) 4.70
Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol (2009) 4.66
Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle (2003) 4.55
The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 4.44
Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol (2007) 4.29
Expanding mTOR signaling. Cell Res (2007) 4.01
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43
PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol (2002) 3.37
FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem (2000) 2.72
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood (2008) 2.53
mTOR and the control of whole body metabolism. Curr Opin Cell Biol (2009) 2.52
The major component in schistosome eggs responsible for conditioning dendritic cells for Th2 polarization is a T2 ribonuclease (omega-1). J Exp Med (2009) 2.34
Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant (2005) 2.32
Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 2.12
Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest (2006) 2.02
Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol (2004) 1.72
Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood (2002) 1.53
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes (2008) 1.49
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol (2008) 1.46
GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood (2006) 1.34
Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol (2008) 1.34
Interleukin-12 inhibits murine graft-versus-host disease. Blood (1995) 1.30
Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood (2002) 1.26
Cutting edge: polarized Th cell response induction by transferred antigen-pulsed dendritic cells is dependent on IL-4 or IL-12 production by recipient cells. J Immunol (2002) 1.26
Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant (2006) 1.24
IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol (2008) 1.22
Inhibition of phosphoinositide 3-kinase enhances TRIF-dependent NF-kappa B activation and IFN-beta synthesis downstream of Toll-like receptor 3 and 4. Eur J Immunol (2005) 1.17
Early administration of IL-12 suppresses EAE through induction of interferon-gamma. J Neuroimmunol (2004) 1.16
Post-transplantation proteinuria and sirolimus. N Engl J Med (2005) 1.03
Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. Oncogene (2008) 1.02
IL-12R beta 2 promotes the development of CD4+CD25+ regulatory T cells. J Immunol (2008) 1.01
Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med (2000) 0.98
Generation, persistence, and modulation of Th0 effector cells: role of autocrine IL-4 and IFN-gamma. J Immunol (1998) 0.93
The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo. Kidney Int (2007) 0.81
Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor. Transpl Immunol (2008) 0.80
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
World review of laparoscopic liver resection-2,804 patients. Ann Surg (2009) 5.96
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol (2007) 4.29
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med (2007) 3.72
Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood (2004) 3.68
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Robotic versus laparoscopic hepatectomy: a matched comparison. Ann Surg (2014) 2.58
Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol (2007) 2.49
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol (2004) 2.38
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant (2005) 2.32
Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26
Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood (2003) 2.12
Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood (2002) 2.02
Laparoscopic major hepatectomy: an evolution in standard of care. Ann Surg (2009) 2.01
Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. Cell Stem Cell (2012) 1.99
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Factors in the pathophysiology of the liver ischemia-reperfusion injury. J Surg Res (2007) 1.89
Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. Arch Surg (2010) 1.85
High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation (2008) 1.85
Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. Arch Surg (2009) 1.82
High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem (2010) 1.79
Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. Ann Surg (2009) 1.74
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
What does the future hold for cell-based tolerogenic therapy? Nat Rev Immunol (2007) 1.64
Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev (2003) 1.61
Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood (2002) 1.53
CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol (2005) 1.52
Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood (2013) 1.48
A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res (2008) 1.48
Tolerogenic plasmacytoid DC. Eur J Immunol (2010) 1.48
Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligand. Blood (2003) 1.43
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol (2006) 1.40
Laparoscopic liver resection. World J Surg (2011) 1.38
Extrahepatic portal vein aneurysm--report of six patients and review of the literature. J Gastrointest Surg (2007) 1.36
miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology (2012) 1.36
Graft versus host disease in intestinal transplantation. Am J Transplant (2004) 1.35
Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol (2009) 1.35
Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res (2006) 1.33
The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant (2005) 1.32
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol (2002) 1.32
Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology (2009) 1.31
Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol (2013) 1.30
"Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol (2006) 1.30
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Comparing the clinical and economic impact of laparoscopic versus open liver resection. Ann Surg Oncol (2009) 1.29
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transplant (2005) 1.26
Laparoscopic resection of benign hepatic cysts: a new standard. J Am Coll Surg (2008) 1.26
Tolerogenic dendritic cells and their role in transplantation. Semin Immunol (2011) 1.26
Identification of a negative response element in the human inducible nitric-oxide synthase (hiNOS) promoter: The role of NF-kappa B-repressing factor (NRF) in basal repression of the hiNOS gene. Proc Natl Acad Sci U S A (2002) 1.25
Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol (2010) 1.24
Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver. Diabetes (2012) 1.22
IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol (2008) 1.22
Cellular-specific role of toll-like receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology (2013) 1.21
Dendritic cells: key to fetal tolerance? Biol Reprod (2007) 1.21
The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.21
Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery (2008) 1.21
Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology (2012) 1.21
Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21
Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg (2007) 1.19
Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation (2005) 1.19
Role of NF-kappaB on liver cold ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol (2002) 1.19
Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol (2008) 1.18
Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J Biol Chem (2001) 1.18
Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol (2002) 1.17
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer (2012) 1.16
Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg (2012) 1.14
Laparoscopic liver resection for cancer. Future Oncol (2008) 1.14
Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J Immunol (2005) 1.14
Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol (2008) 1.12
Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res (2009) 1.12
Genomic organization and expression profile of the mucin-associated surface protein (masp) family of the human pathogen Trypanosoma cruzi. Nucleic Acids Res (2009) 1.12
Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. J Immunol (2013) 1.11
Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem (2003) 1.11
Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett (2011) 1.10
Negligible absorption of radiofrequency radiation by colloidal gold nanoparticles. J Colloid Interface Sci (2011) 1.10
Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation (2007) 1.10
Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells. J Hepatol (2008) 1.10
Ethanol affects the generation, cosignaling molecule expression, and function of plasmacytoid and myeloid dendritic cell subsets in vitro and in vivo. J Leukoc Biol (2006) 1.09
Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res (2004) 1.09
Dendritic cells, the liver, and transplantation. Hepatology (2007) 1.09
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant (2005) 1.09
Dendritic cells under the spell of prostaglandins. Trends Immunol (2003) 1.08
Naturally occurring regulatory T cells: recent insights in health and disease. Crit Rev Immunol (2007) 1.08
Interferon regulatory factor 1 mediates acetylation and release of high mobility group box 1 from hepatocytes during murine liver ischemia-reperfusion injury. Shock (2011) 1.08